header logo image


Page 765«..1020..764765766767..770780..»

New year health kicks are great but your environment is also vital – The Guardian

January 10th, 2020 8:48 am

Exercising and eating better as part of our new year health kicks are great, but we should also think more deeply about the role the environment plays on our health. As a professor of environmental medicine, I believe this is an exciting new area of study that will play a big part in the future of personalized medicine.

Consider this, every day we are bombarded with messages: genes that cause cancer, supplements that prevent Alzheimers disease, diets that prevent asthma, chemicals that make us gain weight. But while headlines frequently proclaim game changing new findings, over the last 20 years in the US and Europe our health status as a population has seriously deteriorated. Rates of obesity, diabetes, heart disease, cancer and learning disorders continue to rise. Genetic variation may be part of the puzzle that explains why we get sick, but clearly there are missing pieces.

After all, 20 years of increasing obesity and diabetes represents only a single generation. If our genes didnt change in the last 20 years, then our environment must have.

Genes never work in isolation. Instead, they determine how we react to our diet, social surroundings, physical environment, infections and chemical exposures. Environment is the missing piece of the puzzle.

The old 20th-century concept of nature v nurture needs to be redefined, as genetics and environment do not compete, they work hand in hand, sometimes to our benefit and sometimes to our detriment. The correct formula is really nature times nurture. Right now the nurture part of that equation is largely unknown, but that may soon change.

Recently, a new concept has arisen, the science of the exposome: the measurement of all the health-relevant environmental factors across the lifetime.

The exposome is to our environment what genomics is to our genetics. Most of what we know about environment and health is still a black box consisting of yet to be discovered risk factors we too often attribute to bad luck ie because we dont measure the environmental cause, the problem appears random.

But most of what we now understand about genetics was also a black box in the 20th century.

Physicians see the role of environment daily even if it is not clear to them that environment is the cause. For example, a child with autism develops more frequent combative oppositional behaviors and emotional outbursts. An adult with diabetes cant seem to control her blood sugar despite higher doses of insulin. A newborn is born with blue skin but a normal heart.

For each of these cases, sequencing the genome would not have identified the cause. The autistic child had lead poisoning because of pica brought on by autism, the diabetic adult used perfumes high in phthalates, chemicals that affect metabolism and the newborn baby drank formula mixed with well water contaminated by fertilizer runoff that reacted with his hemoglobin.

In each case, genomics would not have given us the correct answer, but if we had the tools to measure the exposome, we would have made the correct diagnosis. Just as importantly, because the underlying causes were environmental, we can treat the problem with interventions.

Furthermore, in most diseases, environment and genetics work in combination. Its very rare to have a genetic variant that causes Alzheimers disease, but it is fairly common to have a genetic variant that makes us susceptible to environments that can cause Alzheimers. The different between those with the genetic variant who get sick and those who dont is their different environments.

Imagine a visit to your physician in which you begin by handing over your smartwatch to have its data downloaded, followed by a blood draw to measure your chemical environment and nutritional status, then you update your lifetime home address and occupational history into a secure computer that houses your genomic data. This then computes your personalized risk score for heart disease, diabetes and other diseases. Or, if you already have one of these diseases, computes the ideal treatment regimen based on this big data. This is how we will be able to personalize medicine.

We are not there yet, but the technology to measure the exposome is far more advanced than the general public, and even many researchers, realize. There are now lab tests that can demonstrate the presence of thousands of chemicals in our bodies and satellites that record our daily weather, air pollution, light exposure and built environment. Public records have data on water quality, age of housing, local crime statistics, outdoor noise levels and even where disease clusters are occurring. Cellphones are ubiquitous and can link our daily behavior and movement patterns with the quality of the local air and water while simultaneously measuring our heart rate, physical activity and sleep quality.

Computational science has advanced to a point where storage of terabytes of data is routine and computer clusters are found in every major university and methods to bring these databases together are no longer science fiction. Artificial intelligence and other big data approaches to genomics also provide a roadmap for analyzing exposomic data.

Understanding how environment affects your health will empower people to make the changes in their lifestyle that will matter most. To understand what food to buy, which fragrances to avoid, where and when to exercise, etc. All the pieces to solve this puzzle are beginning to come together. What is needed is the grand vision to invest in and integrate exposomic science into public health and clinical medicine. This is the final piece of the puzzle. Once we understand our exposome and integrate it with our genome, we will finally understand why and how chronic diseases have become so common and how we can start to reverse their trends in society.

Dr Robert Wright is a pediatrician, medical toxicologist, environmental epidemiologist and director of the Institute for Exposomic Research at the Icahn School of Medicine at Mount Sinai

Continue reading here:
New year health kicks are great but your environment is also vital - The Guardian

Read More...

A Few Minutes on the Potential Harm of Predictive Models – Medscape

January 10th, 2020 8:48 am

Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson.

It's a new year. After a little holiday break, I'm back and, frankly, a bit cranky as I peruse the recently published medical literature. I'm focusing today on a rather small study. It's one that hits a pet peeve of mine, so I'm going to channel my inner Andy Rooney here and gripe for a bit.

Appearing in JAMA Network Open, we have this article with the compelling title "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients WithDepression."

I like to know what I'm getting into when I read a title, and this title promises quite a bit. To me, it reads like researchers used electroencephalography (EEG) and some fancy machine-learning stuff to predict which patients with depression would benefit from escitalopram treatment.

That ideausing a machine-learning model to choose the best psychiatric treatment is holy graillevel personalized medicine stuff. See, when confronted with major depressive disorder, docs often try medication after medication to see what sticks; anything to lessen that trial-and-error approach would save tons of time, not to mention lives.

But that is not what this study is about. Walk with me through the methods and you'll see what I mean.

Researchers from British Columbia analyzed EEG data from 122 adult patients with major depression who were initiated on escitalopram therapy.

As you know, an EEG outputs a ton of datamultiple electrodes, thousands of measurements. This is actually an ideal place to use machine-learning tools to squeeze all of those data into a single number. The authors do an exemplary job of using a well-established machine-learning algorithm called a support vector machine to take those gobs of data and turn it into a prediction.

But what exactly are they predicting?

They are predicting whether the patient will have remission of depression in 8 weeks. They are not predicting whether escitalopram was good for the patient, and that difference is huge.

This study had no control group; all 122 patients were treated with escitalopram. We therefore have no way to know whether the machine-learning model identified individuals who are more likely to achieve remission regardless of therapy (let's remember that depression spontaneously remits in around 20% of cases) or those who truly benefit from escitalopram.

See, every patient with depression has four potential destinies in regard to escitalopram:

Some will have remission with or without the drug. Some will never have remission regardless of treatment. Some will only experience remission if they get the drug, and others, presumably, would only not experience remission if they get the drug.

It's really the last two categories we care about in terms of deciding on treatment, but ironically, the first two categories are the easiest to predictbecause in the end, the biggest predictor of whether you get remission from depression is not whether you get a drug but how severe your depression is in the first place.

This is a huge difference in terms of a prediction problem and one that can actually lead to patient harm.

Let me give an example.

Imagine that we built a model predicting who is least likely to have a heart attack among a population receiving simvastatin.

Without a comparator group, we'd find that individuals with lower LDL, more physical activity, and no diabetes would have the best outcomes. If we then argue that these are the types of people who should receive statins, we'd be doing a huge disservice to the people with more severe disease at baseline. Our model doesn't tell us who should get the drug; it only tells us who was better off in the first place.

We need models that can target therapies to the right patients regardless of how sick they are at baseline, or else we'll always choose the least sick people to get treatment. Sure, that will make the success rate of therapies look awesome, but it's not how I want to practice medicine.

Okay, back to escitalopram. What this paper shows us is that the authors built a model based on EEG data that show who is likely to have remission of depression. You could argue that the model has nothing to do with escitalopram. The model may predict outcomes equally well among patients on any antidepressant or on no antidepressant at all. In other words, we're no closer to the dream of strapping an EEG on someone's head and knowing what drug to give them than we were before. But studies like this get reported inaccurately all the time, suggesting that we have some new tool in our personalized medicine toolbox.

My biggest fear is that these models get commercialized as some sort of "use this to decide who to treat" black box, which, as we now all understand, is biased against those who are sicker at baseline, even if they would respond well to therapy. The second sentence of the conclusion of this paper reads: "Developed into a proper clinical application, such a pipeline may provide a valuable treatment planning tool."

Not reallynot unless you want to reserve treatment for the least sick individuals.

Could the researchers prove that their model is not simply identifying less severe depression as opposed to escitalopram response? Well, they could show how their model correlates with baseline depression scores or other baseline factors. My bet is that we'd mostly find that the model just identifies those with less severe depression at baseline, but those data are not presented.

And let's remember that although it's very cool to get data about how severe your depression is just from an EEGI mean, that's Star Trek-y and I love itwe have plenty of tools already available to assess depression severity.

So the next time we see a study (using machine learning or otherwise) that claims to "predict response to therapy," the very next question we have to ask is, "How do we know the model isn't simply identifying less severe disease at baseline?"

F. Perry Wilson, MD, MSCE, is an associate professor of medicine and director of Yale's Program of Applied Translational Research. His science communication work can be found in the Huffington Post, on NPR, and here on Medscape. He tweets @methodsmanmd and hosts a repository of his communication work at http://www.methodsman.com.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
A Few Minutes on the Potential Harm of Predictive Models - Medscape

Read More...

Personalized healthcare and better population health? Heres how digital can help achieve that – The European Sting

January 10th, 2020 8:48 am

(Credit: Unsplash)

This article is brought to you thanks to the collaboration ofThe European Stingwith theWorld Economic Forum.

Author: Paul Hudson, Chief Executive Officer, Sanofi

In November 2019, an Italian surgeon used a virtual reality headset to travel more than 100 kilometres from his location in Rome to an operating room in Terni. His mission? To oversee a laparoscopic procedure being performed in real-time. Thanks to 5Gs low latency, the physician was able to view and zoom in on live images of the patients organs, providing live commentary to the physicians in the operating room. It was a monumental moment for modern medicine, demonstrating the potential of cutting-edge technologies to transform the way we reach and treat patients around the globe.

Innovations like this are becoming more and more common and its clear that technology is going to transform the way that we care for patients around the world from prevention and diagnosis to treatment and beyond. As an industry, were edging closer to personalized medicine and optimized population health, two highly ambitious but important goals. But as we move toward this horizon, we must take care to apply digital innovation strategically across every aspect of our business.

Digital has the potential to fundamentally change the game in R&D and manufacturing, for example:

Relentless R&D engines: I recently visited a lab in Cambridge, Massachusetts, where a robot was operating 24 hours a day, synthesizing 200 proteins at once. It wasnt long ago that a human being would have been tasked with synthesizing all of those proteins, and it would have taken much longer, with more opportunities for error. Scenes like this where technology is embraced and taking over time-consuming, repetitive tasks, freeing human beings to take on more complex, higher-value work are becoming increasingly common in the research and development phase of drug discovery. Scientists around the globe are deploying digitalization to their advantage, and as a result, we are able to understand diseases and reach breakthrough moments faster, which ultimately benefits patients.

Smart manufacturing: Of course, developing treatments faster and more efficiently is just the first step in bringing the right medicines to the patients who need them. Right now, we are at the very beginning of a movement that will improve current manufacturing systems, which often struggle to keep pace with volume and complexity demands. By using leading-edge technology and taking advantage of data to increase efficiencies and improve the agility needed to respond to rapidly changing patient needs, smart factories help to connect the production and distribution processes with R&D. Similarly, the factories are able to quickly change from one manufacturing process to another, greatly limiting the latency time between products and paving the way for the more efficient commercialization of life-saving treatments. These facilities can be up to 160% more productive, increasing factory output by 200% and cutting costs by up to 40%. As equally impressive and important, smart factories are 50% more energy efficient by cutting emissions, reducing pollution and mitigating damage to the environment.

To achieve excellence in both of the areas, the pharma industry must build the foundations necessary for digital to succeed. This includes pursuing company-wide digitalization versus disjointed implementation of the flashiest technologies on the market. To build this foundation, we must ensure that four things happen: firstly, we need to retrain our employees across every division not just in manufacturing or in the lab with the skills they need to work alongside new technologies. In tandem with these efforts, we must also support employees from the factory floor to the C-suite to de-learn old ways of working and embrace a Man + Machine reality.

Thirdly, both of these efforts will require a robust employee engagement movement focused on keeping employees informed of changes and dispelling fears about the Fourth Industrial Revolution. Finally, we need to embrace an industry-wide mindset that celebrates collaboration as the new pathway to innovation. We must have a new open dialogue and partnerships within the innovation environment. If we fail to collaborate and share vital tools such as data, new tools and lessons from start-up pilots, everybody loses. Conversely, if we do all of these things, everyone wins, especially patients.

Of course, these efforts will just scratch the surface of the challenges we face as an industry on our journey to the future of healthcare. But if we focus our energies on equipping our people to succeed and laying the groundwork for digitally enabled companies, digitalization will revolutionize the way we help patients and transform our industry.

Originally posted here:
Personalized healthcare and better population health? Heres how digital can help achieve that - The European Sting

Read More...

Personalized Medicine Market Segment Analysis by Leading Players, Drivers, Regional, Competitive Landscape & Forecast To 2016 2026 – Citi Blog…

January 10th, 2020 8:48 am

Study on the Personalized Medicine Market

The comprehensive report published by Future Market Insights (FMI) offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Personalized Medicine Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Personalized Medicine Market during the forecast period 2016 2026.

As per the findings of the presented study, the Personalized Medicine Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period 2016 2026. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Personalized Medicine in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.futuremarketinsights.co/reports/sample/REP-GB-1511

The presented study addresses the following queries related to the Personalized Medicine Market:

The presented market report dives deep into understanding the business strategies adopted by leading market players in the global Personalized Medicine Market. Further, the SWOT analysis for leading market players is enclosed in the report along with the revenue share, pricing analysis, and product overview of each company.

The extensive study on the Personalized Medicine Market pinpoints the different factors that are likely to influence the prospects of the Personalized Medicine Market in each region.

Decisive Information Enclosed in the report:

Get Access To TOC Covering 200+ Topics athttps://www.futuremarketinsights.co/toc/REP-GB-1511

Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customized Report As Per Your Requirements athttps://www.futuremarketinsights.co/customization-available/REP-GB-1511

Why Buy from FMI?

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

T (UK): + 44 (0) 20 7692 8790

Read this article:
Personalized Medicine Market Segment Analysis by Leading Players, Drivers, Regional, Competitive Landscape & Forecast To 2016 2026 - Citi Blog...

Read More...

EVERSANA and Noom announce strategic partnership to improve therapy adherence and patient engagement for complex therapies – PRNewswire

January 10th, 2020 8:48 am

The partnership combines EVERSANA's fully integrated patient services model with Noom's digital therapeutic platform. Noom's program is based on cognitive behavior therapy and focuses on increasing patient engagement and improving clinical outcomes by leveraging human coaches and artificial intelligence.

"Despite a long road to diagnosis, adherence to therapy falls to 50% - 80% for patients with complex, chronic diseases who routinely deal with difficulties handling side effects, navigating lifestyle changes, and finding the education and resources needed to understand their disease and care," said Jim Lang, CEO, EVERSANA. "By integrating Noom's proven behavioral health technology with EVERSANA's best-in-class patient service programs, we will help manufacturers give their patients the personalized support they have long needed and deserved."

"This relationship with EVERSANA will enable us to engage with a greater number of Life Sciences partners," said Saeju Jeong, CEO and co-founder of Noom. "While we have helped millions of consumers adopt a healthier lifestyle, Noom is more than just a consumer weight-loss company. We have harnessed the power of psychology to help manage patients with both diabetes and hypertension. As a digital companion to drug therapies, Noom is a powerful agent to drive patient engagement and improve health outcomes at scale."

Pharmaceutical and biotechnology companies worldwide face increasing pricing pressures and the need to demonstrate greater value for their products, often measured by therapy adherence, evidence of the lower cost of long-term care, plus patient engagement and satisfaction. Additionally, the promise of regenerative medicine and precision medicine demands the evolution of traditional patient services to meet the complex needs of smaller patient populations.

Both EVERSANA and Noom are widely regarded for leading the evolution of life science services to serve future market and patient needs. EVERSANA has made significant investments in the development of Patient Services 2.0, a high patient-experience-focused model enabled by technology and analytics. Noom's evidence-based curricula and behavioral psychology program is clinically proven through over a dozen published studies and grants from the National Institutes for Health (NIH).

To learn more about the collaboration, visit eversana.com and noom.com to contact company representatives.

CONTACT: Sarah Zwicky sarah.zwicky@eversana.com +1 (414) 434-4691

David Osborne davido@noom.com +1 (917) 575-9133

About Noom, Inc.

Noom is the world's leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,500 personal coaches, Noom helps people live healthier lives by changing their long-term habits. Millions have benefited from Noom's behavior change courses, including its virtual diabetes prevention program, which was the first of its kind to be recognized by the CDC. The Noom platform is already being used by leading healthcare and pharmaceutical companies to improve treatment outcomes for patients worldwide. The company is headquartered in New York City with offices in Seoul and Tokyo.

About EVERSANA

EVERSANA is the leading independent provider of global services to the life science industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product lifecycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.

SOURCE Eversana; Noom

Home

View original post here:
EVERSANA and Noom announce strategic partnership to improve therapy adherence and patient engagement for complex therapies - PRNewswire

Read More...

Personalized Medicine Market : Growing Popularity and Emerging Trends in the Market – ReportsPioneer

January 10th, 2020 8:48 am

Personalized Medicine Market Overview

The Personalized Medicine Market market report provides an in-depth analysis of various market elements that are required for a better understanding of the market. The forecast period mentioned for the study is 2017-2025. Market elements such as market definition, dynamics, research methodology, segments and competitive landscape is used to gauge better market insights. Various factors under the market dynamics section such as drivers, restraints, opportunities and challenges help in adopting various organic as well as inorganic market strategies and approaches. The market estimation for various segments is performed in order to fetch qualitative as well as quantitative insights regarding the market.

Personalized Medicine Market : Market Outlook

Our analysts use various approaches such as primary research and secondary research to fetch the raw data which is further utilized to classify the data on the basis of Top-Down and Bottom-Up Approaches. We also utilize other sources such as industry magazines, government associations, paid databases to validate our data. An executive summary is also provided to our clients helping them to gauge the latest industry trends and forthcoming market insights.

PDF Sample for Current Industry Insights https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=004&utm_campaign=RP

The main objective of the market study is to provide both extrinsic as well intrinsic market insights. The market is broken into smaller segments which helps in building a much more classified market outlook. Each segment is analyzed w.r.t the global market as well as various other micro-markets. Along with the market dynamics, value chain analysis and Porters Five Forces analysis is also provided. Porters Five Forces Model offers insights regarding bargaining power of supplier and consumer along with threats from substitutes and new entrants.

Personalized Medicine Market : Competitive Landscape

The market analysis also encompasses competitive insights for the major industry players and start up ecosystems. In order to fetch insights regarding the positioning of the key industry players, a company ranking analysis is provided. The companies are considered on the basis of following parameters:

Key Player Profiled in the Report Includes Abbott Laboratories, Merck & Co., Inc., AstraZeneca, Pfizer, Inc., GlaxoSmithKline PLC., Novartis AG, Amgen, Inc., Bayer AG, Mylan N.V. and Eli Lilly

Request Discount on the Report https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=004&utm_campaign=RP

About Us-

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. Our large database includes the latest Content from renowned authors and publications worldwide. Weve recently developed one of its own kind smart-system, which helps us determine the authenticity and reputation of the content and its author. This smart-system ensures that we always include high quality content in our database. We also provide customized Data and Reports according to the need of our client. We strive for excellence and perfection in all our work, and our in-house team is working 24/7 so that you get the Data, Reports, and Analytics you need to help make better decisions. We believe in Customer Satisfaction, and to achieve that we aim to understand the clients need to provide tailor-made services.

Our aim is to save your Time and Resources, providing you with the required Research Data, so you can only concentrate on Progress and Growth. Our Data includes research from various industries, along with all necessary statistics like Market Trends, or Forecasts from reliable sources.

Contact Us-

New Jersey ( USA )218 Washington Street,Boonton 07005Tel:+1 (800) 782 1768[emailprotected]

The rest is here:
Personalized Medicine Market : Growing Popularity and Emerging Trends in the Market - ReportsPioneer

Read More...

What to Know in Washington: House to Hold Symbolic Vote on Iran – Bloomberg Government

January 10th, 2020 8:48 am

The House will vote today on a resolution to limit President Donald Trumps options for military action against Iran, with Democrats unsatisfied by the administrations justification for last weeks airstrike that killed a top Iranian official.

The war powers resolution from Rep. Elissa Slotkin (D-Mich.), a former CIA analyst, would require the president to cease military actions against Iran unless authorized by Congress or in response to an imminent threat. A similar measure in the Senate has been introduced by Sen. Tim Kaine (D-Va.).

The vote is mostly symbolic because the Senate version is unlikely to attract much support from the chambers Republican majority and the House resolution by design would never go to the president to become law.

Speaker Nancy Pelosi (D-Calif.) said it is Congresss duty to keep the American people safe, and she said Trumps actions in the region have endangered diplomats and members of the military by escalating tensions with Iran. Pelosi said the Democratic-led House may also soon consider legislation pushed by the partys progressives to cut off funding for action against Iran and repeal existing military authorizations.

Read the BGOV Bill Summary on the House resolution to end hostilities with Iran.

While the Senate resolution has little chance of passing the Republican-led chamber, Kaine did pick up two GOP supporters yesterday: Sens. Rand Paul (R-Ky.) and Mike Lee (R-Utah) say they will support the resolution. Lee said that Trump administration officials left a briefing for lawmakers on Iran after only 75 minutes, adding hed sought more details on the U.S. drone strike on General Qassem Soleimani but White House officials werent forthcoming. Read more from Erik Wasson and Billy House.

Trumps Soleimani Hit Pays Off: Trump took the biggest risk of his presidency by killing a top Iranian general, and for the moment the bet is paying off. The question now is: For how long? A retaliatory Iranian missile attack on two U.S. bases in Iraq early yesterday caused no casualties, allowing the president an opportunity to stand down from what looked like an escalation toward war. We must all work together toward making a deal with Iran that makes the world a safer and more peaceful place, Trump said in remarks to the nation.

The Jan. 2 strike that killed Soleimani was a dramatic show of strength that, at least for now, reset the power dynamic between the U.S. and Iran. Trump appears to believe Iran will now think twice about provoking the U.S. and the two nations could even begin to forge a new understanding to reshape fraught Middle East politics. But its not at all clear that Iran is done with its reprisals. Read more from Justin Sink.

Trump yesterday vowed more sanctions as part of his maximum pressure campaign against Iran. The penalties are likely to target key regime figures and the countrys metals sector, a person familiar with U.S. plans said. The sanctions will likely be aimed at non-oil sectors of the Iranian economy and fit into a previously disclosed administration plan to choke off other sources of revenue now that the U.S. has clamped down on the nations oil exports, said the person, Nick Wadhams reports.

House to Vote on PFAS Bill Thats DOA in Senate: A far-reaching House bill that would force the federal government to address per- and polyfluoroalkyl substances, or PFAS, contamination has little hope of becoming law in its current form, according to the chairman of the Senates environment committee. It has no prospects in the Senate, Sen. John Barrasso (R-Wyo.) said in an interview. None.

Barrassos comments came as the House is swiftly moving toward passage of the bill, which would change the way these persistent and potentially toxic chemicals are regulated. In addition to forcing the EPA to set nationwide drinking water standards for the chemicals, the bill also would require the agency to add the chemicals to its hazardous substance list, which potentially could turn every contaminated location into a Superfund site. Read more from David Schultz.

For more on the PFAS bill, see the BGOV Amendments Summary and BGOV Bill Summary by Adam M. Taylor.

Some Democrats Ask Pelosi to Let Trial Begin: Pelosi will hold her weekly news conference today amid the standoff over sending the impeachment charges against Trump to the Senate. Several Democratic senators are pressuring Pelosi to transmit the impeachment articles and let the Senate trial begin, and one said the trial could start next week.

If were going to do it, she should send them over. I dont see what good delay does, said Sen. Dianne Feinstein (D-Calif.).

Pelosi said she is holding back the articles of impeachment adopted by the House last month until Senate Majority Leader Mitch McConnell (R-Ky.) sets out his rules for the trial. But Sen. Chris Murphy (D-Conn.) suggested the House has little leverage in the matter. My expectation is that well be able to start this trial next week, Murphy said. The leverage over Republicans exists in the votes we take inside the trial. Read more from Billy House and Laura Litvan.

Sekulow to Join Trump Defense Team: Attorney Jay Sekulow will be a member of Trumps defense team for the Senate trial, according to a person familiar with the matter. Sekulow, who became one of Trumps private lawyers in mid-2017, specialized in constitutional issues in the Mueller investigation. White House Counsel Pat Cipollone will lead Trumps legal team for the trial. Separately, Rep. Jim Jordan (R-Ohio) is being recommended by some of the presidents allies to the White House as a possible member of his defense team. Read more from Jordan Fabian and Billy House.

Democrats Unveil Plan for 100% Clean Energy: House Democrats yesterday released ideas for future bills aimed at getting the U.S. to 100% clean energy by 2050 and said theyd work to build support for it in the months ahead. House Energy and Commerce Chairman Frank Pallone (D-N.J.) called the ideas a framework for a measure that will be called the Climate Leadership and Environmental Action for Our Nations Future, or CLEAN Act. The bill hasnt been introduced, and Pallone said draft text would be released around the end of the month. Read more from Dean Scott.

IRS Asked to Advise Nonprofits on Refunds: The IRS should issue guidance instructing tax-exempt organizations how they can claim refunds for overpaid taxes after Congress repealed a portion of the 2017 tax law, House Ways and Means Chairman Richard Neal (D-Mass.) and Rep. John Lewis (D-Ga.) wrote in a letter to the agency. The 2017 tax overhaul required nonprofits to pay a 21% tax on parking and transportation benefits that they offer to employees, but lawmakers repealed the provision in December. Read more from Laura Davison.

FCC Pirate Radio Fines: The Senate unanimously cleared legislation that would allow the Federal Communications Commission to impose up to $2 million in fines against unauthorized radio broadcasters, or so-called pirate radio stations. The bill from Rep. Paul Tonko (D-N.Y.), now heads to the presidents desk. The House passed the bill last February. Read more from Jon Reid.

Trumps Iran Strike Delights Supporters: Trumps loyal political base is standing by his decision to kill a top Iranian general, polls show, even though the move may undermine a key 2016 pledge to end U.S. military involvement in the Middle East. And recent polls show a clean partisan divide on the confrontation. About 67% of Republicans said they either strongly or somewhat approve of Trumps handling of Iran in the days following the U.S. airstrike on Soleimani, according to a Reuters/Ipsos poll released Tuesday. About 69% of Democrats strongly disapprove.

But the political impact of the strike may be most telling among independent voters. About 48% of independents had a negative response to the presidents handling of Iran while roughly 36% answered positively, according to Reuters/Ipsos. And overall, a majority of Americans 53% disapproved of Trumps handling of Iran following the strike, an increase of 9 percentage points from December. Read more from Mario Parker.

Buttigieg Ad Highlights Black Support: Pete Buttigieg is seeking to overcome low support from black voters in South Carolina with a new ad highlighting residents of South Bend, Ind. The 30-second spot avoids any direct mention of race, but it features four black residents praising Buttigiegs record in the city. He listened to our community, says one resident. In recent weeks, Buttigieg has stepped up efforts to win over black voters, who make up the majority of Democrats in South Carolina, meeting with African-American leaders and holding smaller events. Read more from Ryan Teague Beckwith.

DOJ Says Virginias Push for Equal Rights Amendment Futile: The Virginia General Assemblys new Democratic leadership has opened the legislatures session with a pledge to adopt the Equal Rights Amendment. But a U.S. Justice Department official says in a newly released legal opinion that those efforts are in vain, as a 1979 ratification deadline set by the U.S. Congress has passed.

The ERA resolution has expired and is no longer pending before the States, according to Steven A. Engel, assistant attorney general with the Office of Legal Council. That deadline is binding and Congress has to restart the process, Engel said in the memo. Engels legal guidance was issued as Virginia appears to be poised to ratify the amendment. The commonwealth would become the 38th state to approve the ERA, which aims to set a broad guarantee of equal rights under the law, regardless of sex. Read more from Andrew M. Ballard.

Facebook Will Give Users the Option to See Fewer Political Ads: Responding to popular demand, Facebook will soon give users the option to see fewer political and social issue advertisements in their feed. This new setting, which will also be available in Instagram, is part of an effort to give people more control over what they see ahead of the 2020 U.S. presidential election.

Facebook announced the new option Thursday in a broader update about political ads on the service. The company did not, however, announce major changes or restrictions to the ad-targeting tools available to political campaigns. Facebook has discussed potential changes to ad targeting internally in recent months following restrictions from rivals Google and Twitter Inc. The social network decided against changing its targeting tools, which can be very granular and specific, after extensive outreach and consultations with third parties, the company said in a blog post.

Facebook is also sticking with a controversial policy that stipulates the company will not fact-check posts from politicians, including political ads. Read more from Kurt Wagner.

(Michael Bloomberg is also seeking the Democratic presidential nomination. Bloomberg is the majority owner of Bloomberg Governments parent company.)

Kuwaiti Cash Fuels Misleading U.S. Media Coverage: A business executive accused of financial crimes in Kuwait is getting support from an all-star cast of famous Americans, including a son of the U.S. president who liberated the Gulf nation and several of Trumps allies. Theyve helped generate a torrent of sympathetic media coverage from the Middle East to Washington. The boldface names are part of a $4.9 million campaign that also has been marked by subterfuge and deception, including a fake protest, thousands of dollars in payments to some U.S. opinion writers, misleading news reports and a correspondent who may not exist. A review of government filings and an examination of dozens of articles shows just how easily money can warp U.S. press coverage. Read more from Zachary R. Mider, Benjamin Elgin and Joe Light.

Chinas Liu He to Travel to U.S. for Trade Deal Signing: China announced that Vice Premier Liu He will travel to Washington to sign the first phase of the trade deal with the U.S. next week, locking in Beijings commitment to a ceremony already announced by Trump. Liu, who has acted as Chinese President Xi Jinpings top trade negotiator throughout the tariff conflict, will travel to the U.S. from Jan. 13 to Jan. 15 at the head of the delegation, Ministry of Commerce spokesman Gao Feng said today in Beijing. He said he has no more information to release about the trade talks, other than that the teams remain in close contact. Read more.

Medical Testing Sector Awaits Court Clarity on Patents: Medical companies that develop tests to diagnose neurological disorders, heart disease risk and fetal abnormalities have been in legal limbo since a 2012 Supreme Court ruling that limited the patenting of such tests, finding they occurred in nature and were not invented. The high court may signal as soon as tomorrow whether it will revisit the subject as such tests become critical to the burgeoning field of personalized medicine, in which doctors determine whether a patient is genetically susceptible to a particular disease or would respond to certain treatments. Read more from Susan Decker.

The Cost of IRSs Failure to Collect From Tax Cheats: The average U.S. household is paying an annual surtax of more than $3,000 to subsidize taxpayers who arent paying all they owe, a new report from the Taxpayer Advocate Service found. Reduced funding for the Internal Revenue Service has led to lower staffing levels and fewer audits, which has reduced the amount the IRS has been able to collect from taxpayers voluntarily or through enforcement, the Taxpayer Advocate, an independent branch of the IRS, said in its annual report to Congress yesterday. Read more from Laura Davison.

Private Push for Trump Wall Hits Legal Snags: An effort to build pieces of Trumps Mexico border wall using private funding and land has run into an unlikely obstacle the federal government. The U.S. International Boundary and Water Commission isnt exactly a core pillar of the Trump administration. But with help from the top federal prosecutor in southern Texas, the agency is pushing back against the likes of Steve Bannon and other Trump allies who are trying to put up an 18-foot tall bollard-style barrier along a 3 1/2-mile stretch of the Rio Grande that they claim is used for illegal border crossings and drug smuggling. Read more from Peter Blumberg and Tom Korosec.

To contact the reporters on this story: Zachary Sherwood in Washington at zsherwood@bgov.com; Brandon Lee in Washington at blee@bgov.com

To contact the editors responsible for this story: Giuseppe Macri at gmacri@bgov.com; Loren Duggan at lduggan@bgov.com

Continued here:
What to Know in Washington: House to Hold Symbolic Vote on Iran - Bloomberg Government

Read More...

Disruptive Technologies in Pharma 2020 – the "Healthcare Disruptors" – – pharmaphorum

January 10th, 2020 8:48 am

SMi has released an exclusive interview with industry expert Shikta Das, Independent Senior Data Scientist, ahead of the upcoming Disruptive Technologies in Pharma conference this January.

Disruptive Technologies in Pharma will bring together experts in pharma technology to explore the latest developments within artificial intelligence, machine learning, IoT, digital therapeutics, eHealth and blockchain, highlighting the challenges of implementation and how to overcome them.

During the run-up to the conference, SMi interviewed industry expert and conference speaker Shikta Das, an Independent Senior Data Scientist. Here is a snapshot of what was discussed:

What is your background in disruptive technologies and which technologies have you been involved with throughout your career?I have been a research scientist most of my career and recently started working with the pharma industry as a Data Scientist. My undergraduate degree was in Zoology and I became fascinated with the advances in genomics with the human genome coding in 2001. Therefore, I decided to study for an MSc in Bioinformatics from Birkbeck, London. That MSc opened the door to Imperial College Londons Bioinformatics team, working with pioneering bioinformatics research. I loved Imperials open mindedness and focus on innovation and decided to purse my PhD there. I thoroughly enjoyed that rigour and became a well acknowledged PhD. To be honest, I have never looked back since then.

I had long been at the edges of Data Science I have been handling large amounts of data and running statistical modelling on clinical datasets, both of which seemed fundamental requirements for data science nowadays. I have continued to gain good coding experience in R since my MSc days and a great passion for personalized medicine- it is no accident that I have ended up in pharma! Also as I was very keen on learning prediction from data, I got involved with ML.

As a data analyst in healthcare, what is your insight on the digital transformation process of the healthcare sector and the need for such transitioning?In my work, I spend a lot of time thinking about qualitative and quantitative data and connecting digital technologies with predictive models

To read the full interview, visit: http://www.disruptivetech-pharma.com/pr8

Shikta Das will be presenting on Healthcare Disruptors, which will cover recent advances in using AI in Healthcare and the impact of AI in Healthcare.

Disruptive Technologies in Pharma20th 21st January 2020London, UK

ENDS Contact Information:For media enquiries contact Neill Howard on +44 (0)20 7827 6164

View post:
Disruptive Technologies in Pharma 2020 - the "Healthcare Disruptors" - - pharmaphorum

Read More...

Ionis finds new partner in a young biotech and its hopeful founder – Endpoints News

January 10th, 2020 8:48 am

Omri Gottesman came to the US from the UK 10 years ago, wide-eyed like many others.

The human genome project was long-complete and, with great fanfare, researchers were beginning to try and leverage those insights into treatments. Mount Sinai School of Medicine offered him a fellowship focused on just that: genomic medicine.

At the time, there was a lot of hope and hype that we had solved health, and would be able to discover and prevent everything and treat everyone, Gottesman told Endpoints News. It was the reason I came to Mount Sinai.

Over the ensuing decade, human biology proved much more elusive than they imagined. Genetics was more complicated than A-T and C-G. There were no easy hacks. Still, the field advanced and after 4 years at Mount Sinai and a stint at Regeneron, Gottesman decided he wanted to advance it on his own and build a new platform around the original mission: Analyze genetic information to home in on ideal drug targets. He called the new company Empirico and soon raised $30 million.

Its not a unique concept, but its one Gottesman pulled off well enough to today score a three-year partnership with Ionis Pharmaceuticals, one of the oldest and more successful genetics-based drug developers.

Ionis will make a $10 million equity investment into Empirico and offer $30 million in near-term operational and preclinical milestones, with another $620 million promised for clinical, regulatory and sales goals. In exchange, Empirico will make up-to 10 platform-discovered drug targets available to Ionis.

We spent about a year building the discover-first platform, Gottesman said. Part of the motivation for the Ionis collaboration and exploring collaborations more broadly is that we now have more potential targets than our capacity to develop therapies for them.

On the Ionis side, this is the latest collaboration for a biotech that has sought many since its founding and is trying to keep early-stage strong while some late-stage programs come to fruition. The deal also includes an option for Empirico to license a drug back from Ionis as it strives to become a target-to-market company.

Youve heard of platforms like Empirico before; its the mixed machine learning and wet lab approach taken by a growing number of biotechs. Gottesman and his team use their computer platform to interrogate genetic data for the roots of diseases. Should the computer find a mispelling or other variant in genetic code that appears to cause the malfunction, they then produce cell lines with that mispelling in the lab. Should those cell lines show the same malfunction as the disease, they then use their platform to identify the best form for a therapy.

Theyve used that method to build 5 preclinical targets, leading to a small molecule program for an upper airway disease and an siRNA candidate for glaucoma.

The targets for the Ionis collaboration will be those Empirico finds can be best-treated with their partners signature antisense technology. The biotech has already identified a couple, although they didnt disclosed them.

A 40-year-old concept, antisense therapies have recently brought some of the genetics-based health gains Gottesman and others sought. Along with a handful of approved drugs, last year a neurologist in Boston created a personalized therapy for a young girl with a never-before-seen genetic error. And yesterday, Ionis founder Stanley and Rosanne Crooke launched a charity to make those kinds of genetics-based ultra-personalized medicines broadly accessible.

Those bespoke therapies are arguably the apex of the vision Gottesman and others had 10 years ago. Its a vision he thinks has made more progress than some think, even if it hasnt brought any utopian dream.

Over the last decade, weve realized its really harder than it seems, he said. But actually, if you work at it, theres real value.

Social image credit: Ionis via YouTube

Link:
Ionis finds new partner in a young biotech and its hopeful founder - Endpoints News

Read More...

Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia – A Free Webinar from the Brain & Behavior Research Foundation -…

January 10th, 2020 8:48 am

New York, Jan. 08, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia on Tuesday, January 14, 2020, from 2pm to 3pm ET. Gregory A. Light, Ph.D., University of California, San Diego, will be the presenter.

Dr. Light will describe precision medicine trials his team has conducted which significantly reduced symptoms and improved cognitive and daily functioning in patients with chronic psychosis in a real-world setting: a long-term community inpatient facility. They also found that reliable, easy-to-obtain signatures of brain-wave activity recorded at the outset of treatment can be used to identify which patients are most likely to benefit (or not) from treatments. This work ultimately aims to develop personalized biomarker assessment tools to deliver the right treatment to the right person at the right time, to improve outcomes among the millions of people with psychotic disorders, most notably schizophrenia.Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation and Host and Executive Producer of the public television series Healthy Minds, will be the moderator. Join by phone or on the web at bbrf.org/januarywebinar.

This webinar is part of a series of free monthly Meet the Scientist webinars on the latest developments in psychiatry offered by the Brain & Behavior Research Foundation.

The Brain & Behavior Research Foundation The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia, as well as research on suicide prevention. Since 1987, the Foundation has awarded more than $408 million to fund more than 4,800 leading scientists around the world, which has led to over $4 billion in additional funding. 100% of every dollar donated for research is invested in research grants. BBRF operating expenses are covered by separate foundation grants. BBRF is the producer of the Emmy nominated public television series Healthy Minds with Dr. Jeffrey Borenstein, which aims to remove the stigma of mental illness and demonstrate that with help, there is hope.

Go here to read the rest:
Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia - A Free Webinar from the Brain & Behavior Research Foundation -...

Read More...

Invest With A Purpose: Own The Future With Megatrend ETFs – Forbes

January 10th, 2020 8:47 am

We now drive electric cars, watch our favorite shows on mobile devices, attend concerts via virtual reality and control the temperature in our homes by giving instructions to a voice assistant.

Technological innovations like these underpin the transformative forces that are changing how we live and work.

You can harness the growth potential of these powerful forces by investing in megatrend ETFs.

An ETF (exchange-traded fund) is a diversified collection of securities (like a mutual fund) that trades on an exchange (like a stock). Megatrend ETFs capture targeted groups of stocks perceived to be well-positioned to benefit from shifts in technology, society, the environment and demographics over time.

Here's why megatrend ETFs are the next frontier of access and a glimpse at the five megatrends BlackRock sees at the forefront of our changing world.

With megatrend ETFs, iSharesBlackRock's ETF businessoffers individual investors access to opportunities that were once available primarily to institutional investors able to qualify for venture capital, private equity and other private market investments.

This is unlike sector indexes (like Technology or Communications) that more rigidly track companies within a single sector, or broad indexes (like the S&P 500) that track a universe of companies across many industries and are weighted heavily toward larger, more established companies rather than smaller, more disruptive players.

As an example, with megatrend ETFs, investment in the self-driving and electric vehicles trend would go beyond carmakers and also include hardware companies that make road-monitoring sensors, software companies that make the algorithmic "brains" required to guide vehicles as well as battery producers. By looking beyond sectors and regions and selecting companies that are leaders in a particular ecosystem, investors can access the full growth potential underpinning these trends.

Megatrend ETFs are also transparent and easy to own, removing the need to pick single-stock winners, which has proved difficult for investors to successfully do. With the potential to capture long-term growth opportunities, megatrend ETFs can be seen as complementary holdings to your core portfolio.

BlackRock has identified five megatrends shaping our future. Here's a look at each and how they can help position you for tomorrow.

Technology is such a prevalent force that the current era has been dubbed the Fourth Industrial Revolution. How you live and work is shaped by exponential technologies like artificial intelligence, 3D printing and synthetic biology, to name just a few. Technology is driving exponential progress in the tech sector and far beyond and underpins the other megatrends we'll mention shortly.

You can tap into the firms harnessing technology to solve privacy threats by investing in iShares Cybersecurity and Tech ETF.1 The fund seeks to track the investment results of an index composed of companies involved in cybersecurity and technology, including cybersecurity hardware, software, products and services.

Longer lifespans and modern lifestyles will change medicine and consumer habits. If you are fascinated by the possibilities of medical technology, consider ETFs that target companies at the forefront of medical progress. iShares Genomics Immunology and Healthcare ETF2 is one such option. This ETF seeks to track the investment results of an index composed of companies that could benefit from the long-term growth and innovation in personalized medicine: genomics, immunology and bioengineering.

It's expected that more than two-thirds of the world's population will reside in cities by 2050, double the percentage from 1950.3 This mass migration to cities will require new business models and infrastructure.

If you would like to invest in companies that may benefit from this megatrend, consider iShares U.S. Infrastructure ETF.4 The fund seeks to track the investment results of an index composed of equities of U.S. companies that have infrastructure exposure and could benefit from a potential increase in domestic infrastructure activities. This ETF offers access to two groups of infrastructure companies that are equally weighted: owners and operators, such as railroads and utilities, and enablers, such as materials and construction companies.

Demand for a clean, green tomorrow will advance energy and conservation. If you drive, or would like to drive, an electric car, you may be interested in putting your money in an ETF with an environmental focus. iShares Self-Driving EV and Tech ETF5 seeks to track the investment results of an index composed of companies that may benefit from growth and innovation in and around electric vehicles, battery technologies and autonomous driving technologies.

It's expected that the number of newly affluent consumers will expand in Asia and across emerging markets. For example, China now has 3.5 million millionaires and more residents with wealth above $50 million than any country except the United States.6 iShares MSCI China A ETF7 can provide access to the Chinese market as it tracks the investment results of an index composed of domestic Chinese equities that trade on the Shanghai or Shenzhen Stock Exchange and are not well-represented in broad benchmarks.

Every day, you witness how megatrend-driven innovations are transforming our world. With iShares megatrend ETFs, you can invest in the future today.

For more information on how ETFs can help you invest in our changing world, click here.

Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the Funds' prospectuses or, if available, the summary prospectuses, which may be obtained by visiting http://www.iShares.com or http://www.blackrock.com. Read the prospectus carefully before investing.

Investing involves risk, including possible loss of principal.

Go here to see the original:
Invest With A Purpose: Own The Future With Megatrend ETFs - Forbes

Read More...

Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference – Yahoo Finance

January 10th, 2020 8:47 am

Press release

Gosselies, Belgium, 9 January 2020, 7 am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address highly unmet medical needs in orthopaedics and bone diseases, today announces that Chief Executive Officer, Dr. Miguel Forte, MD, PhD, will attend the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, 13-16 January 2020.

If you would like to meet with Dr. Miguel Forte from Bone Therapeutics at the conference, please contact investorrelations@bonetherapeutics.com.

The Company will also host, in collaboration with Arrowhead Business and Investment Decisions, LLC investor meetings in New York and Boston on 23 and 24 January.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis following the positive Phase IIb efficacy results in patients with knee osteoarthritis which showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) to start the pivotal Phase III program has been submitted to the regulatory authorities in Europe and the trial is expected to start in Q1 2020.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the strong Phase IIa efficacy and safety results for ALLOB, the Company plans to submit a CTA with the regulatory authorities before year-end 2019 to initiate a Phase IIb clinical trial with ALLOB in patients with difficult-to-heal fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at http://www.bonetherapeutics.com.

Contacts

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Consilium Strategic CommunicationsMarieke VermeerschTel: +44 (0) 20 3709 5701bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Story continues

View post:
Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference - Yahoo Finance

Read More...

HIV drug resistance an emerging threat, expert warns – DAWN.com

January 10th, 2020 8:46 am

KARACHI: There is an urgent need for educating people on the means of transmission and prevention of sexually transmitted diseases and address the social stigma and fear attached to HIV/AIDS. A potentially life-threatening disease, HIV/AIDS, has reached alarming proportions in the country, also reporting drug resistance in patients on medications.

These points were highlighted by Dr Saeed Khan, a professor of pathology associated with the Dow International Medical College, at the last day of a three-day conference titled PROBE (Physiology Resonates and Ozonizes Biological Existence) 2020 Conference organised by the department of physiology at Karachi University (KU).

The Human Immunodeficiency Virus (HIV) is the causative agent of AIDS that causes patients immune system to become ineffective and exposes the body to secondary infections. In Pakistan, the HIV-1 subtype A has been observed to be more prevalent among different high-risk groups, including injection drug users, said Dr Khan.

According to him, Pakistan, which was earlier reporting low prevalence of HIV/AIDS, now has concentrated epidemic in high-risk groups with greater presence of HIV-1 subtype.

Over the past few years, however, it has been observed that several different HIV subtypes and recombinant forms are circulating [in] the country, also reporting cases with drug resistance in patients receiving medications, he explained, adding that drug resistance might also be due to treatment failure.

Larkana outbreak

He also spoke about the HIV outbreak in Larkana and referred to the Sindh AIDS Control Programme statistics according to which 26,041 people had been screened for HIV since the start of the outbreak and 751 people were tested positive for the disease.

The root cause or transmission factors behind this epidemic are still a mystery and the data on the molecular characterisation, drug resistance and its origin of spread is not available.

Talking about HIV prevention and effective treatment and rehabilitation, Dr Khan said it was important to address the social stigma, fear of social disapproval and denial of accepting the reality in response to this disease.

In our culture, topics related to sexual encounters and safe sex are considered as a taboo so they are not openly discussed, increasing vulnerability of population especially of the youth to the infection.

He emphasised that society must take steps to reduce the stigma related to HIV/AIDS so that people could speak up and talk about the disease and its modes of transmission.

This will also increase social acceptance of people living with HIV and help them attain their fundamental rights to quality education, health and better employment. In this respect, we all need to play a positive role since we know that government resources are limited, he said, adding that no one was safe unless everyone was safe.

Thalassaemia management

Dr Saqib Hussain Ansari, a consultant haematologist and bone marrow transplant physician at Childrens Hospital Karachi, talked about thalassaemia management without blood transfusion and said it had a great prospect especially in the middle- and low-income countries where the burden of transfusion transmissible infections and iron overload were increasing.

According to him, stem cell transplantation (in Pakistan) is not a practical option due to multiple factors, for instance financial costs, donor unavailability and scarcity of transplantation facilities.

Referring to some data, he said the childrens hospital registered 1,135 patients with beta thalassaemia between January 2004 and December 2017. Of them, 221 left treatment for different reasons.

Focusing on the challenges posed by diabetes, Prof Mohammad Kamran Azim, dean of the faculty of life sciences at Mohammad Ali Jinnah University, said Type-2 diabetes had emerged as a growing health issue affecting more than 170 million individuals worldwide.

Citing WHO statistics, he said the number of Type-2 diabetes patients in Pakistan was expected to rise from 4.3m in 1995 to 14.5m in 2025, making Pakistan the fourth most diabetes-affected country in the world.

Scientists, he pointed out, had not yet fully understood this disease. Though its well known that diabetes is associated with inflammation and altered immune response, the specific cellular and molecular mechanisms involved in the disease are yet to be fully understood, he said.

Dr Syed Aqeel Ahmed, chief operating officer at the Tabba Kidney Institute, also spoke.

A large number of students and researchers participated in the conference, including those from the Bahauddin Zakaria University (Multan), Islamia University (Bahawalpur), University of Health Sciences (Lahore) and University of Sindh (Jamshoro).

Partnered with the Pakistan Physiological Society and the South Asian Association of Physiologists, the event was supported by the Higher Education Commission Pakistan, the Pakistan Science Foundation, the Office of Research, Innovation and Commercialisation and the World Poultry Science Association.

Published in Dawn, January 10th, 2020

Go here to read the rest:
HIV drug resistance an emerging threat, expert warns - DAWN.com

Read More...

A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences – alleghenyfront.org

January 10th, 2020 8:46 am

Tommy Joyce is no cinephile. The last movie he saw in a theater was the remake of True Grit nearly a decade ago. Id rather watch squirrels run in the woods than sit through most of what appears on the big screen, he said.

But theres a film that opened Dec. 5 at the Regal Cinemas at Grand Central Mall thats attracting a lot of attention in his community. Dark Waters a legal thriller starring Mark Ruffalo, with a script inspired by a 2016 New York Times article tells the epic story of the DuPont corporations failure to inform residents of the Mid-Ohio Valley of the considerable health risks of a perfluoroalkyl substance [PFAS] called perfluorooctanoic acid, or C8, for its chain of eight carbons.

The chemical was used in DuPonts production of Teflon and other household products at its Washington Works facility just outside Parkersburg, along the Ohio River. C8 is found in nonstick pans, waterproof clothing, stain-resistant carpets, microwave popcorn bags, fast-food wrappers and hundreds of other products. According to a 2007 study, C8 is in the blood of 99.7% of Americans. Its called a forever chemical because it never fully degrades.

DuPont had been aware since at least the 1960s that C8 was toxic in animals and since the 1970s that there were high concentrations of it in the blood of its factory workers. DuPont scientists were aware in the early 1990s of links to cancerous tumors from C8 exposure. But company executives failed to inform the Environmental Protection Agency [EPA] or the public.

Weathered signage on the Point Park floodwall greets passersby in downtown Parkersburg, West Virginia. Photo: Lexi Browning/100 Days in Appalachia

Joyce graduated from Parkersburg High School in 1992, went off and earned three degrees and came home. He now serves as mayor of the city of Parkersburg population: 30,000.

Joyce said hes heard more about his communitys long struggle with corporate environmental malfeasance in the past few weeks than in his previous two and a half years in office. He attributes this to the release of Dark Waters.

Even David-and-Goliath tales often have complicated backstories, and Joyce knows well that such is the case with Parkersburg and DuPont. DuPont has been in the Ohio Valley for 70-plus years, and has been a tremendous employer, he said. Without question, DuPont was the place to work in the Mid-Ohio Valley for a lot of years. Many of his classmates grew up in DuPont families.Though Chemours, a spinoff company of DuPont, now operates the Washington Works plant, DuPont maintains a presence in the community. A DuPont spokesperson provided an overview of its financial and volunteer support initiatives and wrote that the company supports programs and organizations focused on revitalizing neighborhoods and enhancing quality of life; STEM-related initiatives in local schools; and initiatives that help protect the environment through clean-up or restoration efforts and allow for DuPont Washington Works to show we are a leader in minimizing our environmental footprint within the community.

A probable link between C8 and six conditions: testicular cancer, kidney cancer, thyroid disease, ulcerative colitis, pregnancy-induced hypertension and high cholesterol.

Parkersburg, said Doug Higgs, is the kind of town where everybody knows everybody. Higgs graduated from Parkersburg High a year after Joyce, and Joyces mother, Barbara, taught him Sunday school.

Everybody knows everybodys business, Higgs said, but nobody talked about C8. It was a matter of not wanting to bite the hand that fed you.

Well-paying jobs, great benefits, Little League sponsorships, investments in the arts but at a cost. The hand that fed did clench.

Higgs, now an emergency room physician living in Richmond, Virginia, recalls returning from road trips with his family asleep in the back seat, awakened as they approached home by the familiar waft of chemicals.

Two of the Higgs most immediate neighbors died in their early 50s of renal cell cancer. Higgs father has ulcerative colitis, and his brother received treatment for polycystic kidney disease in high school.

We all have stories of friends and family, neighbors, dying too young or being diagnosed with various medical problems, Higgs said.

He knows, of course, the distinction between correlation and causation. But the high incidence of a range of diseases has staggered this community. Its unfair, Higgs said, that a community should have to perpetually ask what exactly it has been exposed to, and where and when the consequences will end.

An aerial view of Parkersburg, West Virginia, taken from Fort Boreman Park. Photo: Lexi Browning/100 Days in Appalachia

A vehicle slows down at the corner of Fourth and Market streets in Parkersburg, West Virginia. Photo: Lexi Browning/100 Days in Appalachia

DuPonts own documentation specified that C8 was not to be flushed into surface waters, but the company did so for decades. The chemical seeped into the water supplies of the communities of Lubeck and Little Hocking, immediately west of Parkersburg, and the city of Belpre, Ohio, just across the river; and three other water systems.

In 2004, DuPont paid $70 million in a class-action lawsuit and agreed to install filtration plants in the affected water districts. In 2005, it reached a $16.5 million settlement with the EPA for violations of the Toxic Substances Control Act.

Ohio River Communities are Still Coping with Teflons Toxic Legacy

A collective decision was made to use the money won in the class-action suit to conduct an epidemiological study in which nearly 70,000 of the 80,000 plaintiffs stopped into one of six clinics set up throughout the community, provided their medical histories and offered their blood. They were each paid $400.

A science panel, comprised of public health scientists appointed by DuPont and lawyers representing the community, was convened to examine the immense database. In 2012, after seven years of study, the panel released a report documenting a probable link between C8 and six conditions: testicular cancer, kidney cancer, thyroid disease, ulcerative colitis, pregnancy-induced hypertension and high cholesterol.

In 2015, DuPont spun off its chemical division into a new company called Chemours, which now occupies the Washington Works facility on the Ohio. In 2017, DuPont and Chemours agreed to pay $671 million to settle some 3,500 pending lawsuits.

The Washington Works facility, formerly of DuPont, in Parkersburg, West Virginia, is seen from across the Ohio River. Photo by Lexi Browning/100 Days in Appalachia

You grew up with the fear of DuPont leaving town, said Ben Hawkins. Hawkins was student body president of the Parkersburg High class of 1993. He remembers DuPonts participation in his schools Partners in Education program and riding in parades on DuPont-sponsored floats.

Among Hawkins classmates who have been diagnosed with pancreatic cancer was Mike Cox, a local dentist. Cox, Hawkins and Higgs were among a pack of guys who ran together in high school and stayed close after. Cox was a big Ozzy Osbourne fan, and after a grueling regimen of chemo, Hawkins helped arrange backstage passes to a concert, where Osbourne pulled Cox near and shared his own familys experience with cancer. Post-diagnosis, Cox had begun performing stand-up comedy routines that incorporated flute solos. He died Jan. 28, 2017, at the age of 41, a father of three.

Hawkins, who now lives in the Washington, D.C., area, views his Partners in Education experiences somewhat differently today: It wasnt a partnership; it was a page from a public relations playbook. It was the old hey-look-over-here! move to keep the Teflon dollars flowing into their bank account.

His classmate Beth Radmanesh has similar cynical recollections of DuPonts role in her childhood. Radmanesh grew up less than a mile from the Washington Works plant. Today, she has high cholesterol. Her dad suffers from discoid lupus, causing sores the size of 50-cent pieces on his forehead. Her brother has lupus and had colon cancer, and her sister-in-law has also been diagnosed with lupus.

But Radmanesh said her mom is a proponent of bringing another controversial industry to the valley: fracking for natural gas. I said to her, Weve already had our water contaminated once. Do you want your water [to be] flammable? Because thats what will happen. Her moms response was, Oh, Beth. Thats it. Oh, Beth.

Joe and Darlene Kiger live just a few miles from where Radmanesh grew up. Joe, a physical education teacher, is now quite well known in the community for having raised awareness of the dangers of C8 called the devils piss by some in local water supplies. He and his wife, Darlene, joined the class-action suit that was settled in 2004.

Darlene said that when she and Joe are out around town, there are a lot of whispers behind your back. They dont know what to say. The experience has taken a toll these people all looking at you as bringing this on them, Joe said but theyve never considered leaving. Why would you leave the fight? he said. What would it look like if we packed up?

Theres a lot, Joe said, that DuPont hasnt yet been held accountable for. Earlier this year, Chemours was cited by the EPA for the unregulated release of new chemical compounds from its West Virginia and North Carolina facilities. Im not done yet, Joe said.

Joe Kiger and his wife Darlene Kiger are photographed at their residence in Washington, West Virginia. The Kigers have spent the last two decades working to uncover the impacts and effects of C8 exposure in the region. Weve been through hell over the last 20 years, Joe Kiger said. Photo: Lexi Browning/100 Days in Appalachia

Attorney Harry Deitzler poses for a portrait in his office at Hill, Peterson, Carper, Bee and Deitzler, PLLC, in Charleston, West Virginia. Deitzler was involved in settling the C8 groundwater contamination suit against DuPont in Parkersburg, WV. Photo: Lexi Browning/100 Days in Appalachia

Harry Deitzler served as a lead attorney, among others, in representing the Kigers and tens of thousands of others in the class-action suit. Deitzler was the architect of the decision to use the $70 million to conduct the study.

Parkersburg adopted me in 1975, Deitzler said of his arrival in town. Hed come for a summer internship in the prosecuting attorneys office. The position didnt pay enough to cover his room and board, so he took a job in a bar called Friar Tucks.

By the end of the summer, the community was my family, Deitzler said. I asked the prosecutor if hed hire me as an assistant the next year, and he said, Sure; youll get $6,000 a year. And I said, Thatll be great.

Most people thought I was a recovering alcoholic because I never drank a beer, because I couldnt afford to buy one. Three years later, at 27, he was appointed as prosecuting attorney. Such a wonderful, accepting community.

But, some three decades later, there was a price to pay for taking on DuPont.

There was a misperception that we were trying to put DuPont out of business, and, of course, that was created intentionally by the people in Wilmington, Deitzler said, referring to DuPonts Delaware headquarters. When you have a community of that size, and youve got several thousand people employed there, and multiply that by the families and their relatives its very upsetting. Some folks were unsure of what to make of Deitzler.

Longtime resident Nancy Roettger characterizes the communitys reaction to the revelation of what DuPont had done as a weird mix.

There were women that immediately went out and changed their frying pans, Roettger said. But a lot of those same people decided that Harry Deitzler is a horrible person for his role in exposing DuPont.

Its like, they dont want that frying pan anymore, she said, but they dont want anything negative, and theyre very resentful of the people that stirred up the trouble.

Candace Jones, a neighbor and longtime friend of Roettgers, said she hates the perception that the community has been divided between the DuPonters and everyone else.

Were a community and we all need each other, Jones said. I think its terrible, absolutely horrendous what happened because of decisions made for monetary gain. But I dont believe we can blame the everyday worker. Her father-in-law worked in the Teflon division. He just went to work every day; he provided for [his family].

Candace Jones, a native of Vienna, WV, is photographed downtown. Jones, who has lived in the area for most of her life, recalled DuPonts heavy involvement in the community, from sponsoring community activities and education to employing a great deal of the areas residents. (Photo by Lexi Browning/100 Days in Appalachia

Tracy Danzey grew up in Parkersburg, West Virginia, but now lives on the opposite side of the state in its Eastern Panhandle. Danzey was diagnosed with a rare form of bone cancer that led to the amputation of her leg. Doctors couldnt trace the cause of the cancer, but Danzey believes it was caused by exposure to industrial waste in the waters of Parkersburg that she drank and swam in. Photo courtesy of Seth Freeman Photography

Jones friend Janet Rays husband passed away 16 years ago from pancreatic cancer. He worked for BorgWarner, a manufacturing company on the river. There are about a dozen houses along Rays street in Vienna, a Parkersburg suburb, and I think just about every house during the time Ive lived on the street has been affected by cancer.

Ray said she sometimes feels guilty, thinking that perhaps the livelihood her family has enjoyed as a result of her husbands employment might have caused health problems for others. I certainly hope it didnt.

Tracy Danzey was raised in the quiet of Vienna, there with the Rays, the Joneses, the Higgs family. She now lives on the other side of the state, in West Virginias Eastern Panhandle. Danzey was a competitive swimmer growing up. When not competing, we were on the river we were playing in the creeks. I was always in the water.

Its hard to look back at that time now and see it as idyllic, Danzey said.

At age 20, her thyroid began malfunctioning. Five years later, the socket of her hip shattered while running with her husband. She was diagnosed with an atypical form of bone cancer in her right hip. Her hip and leg had to be amputated; she underwent 18 months of high-dose chemotherapy.

Six leading pathologists from across the country were unable to identify the specific type of cancer. They said its very pathologically unusual. Research has indicated to Danzey, whos a nurse, that pathologically unusual cancers are not uncommonly associated with industrial poisonings.

Danzeys stepfather is retired from DuPont and her stepbrother works on the Teflon line. Yes, it is complicated, her mother, Carolyn Tracewell, said. When her kids were growing up, when someone was hired at DuPont, therewas a celebration the good pay, the benefits, and they did treat their employees well.

But my heart hurts, Tracewell said, to think that her daughters illnesses might be a consequence of all that.

Danzey said her mom mostly just feels pain for me, worries about her stepson and is anxious about the future. Her stepfather wonders if one day his pension check will no longer arrive as a result of all the financial fallout.

None of them argue with Tracy about the source of her illnesses. They know what happened. They allow her to sit in this truth regardless of how it affects them. That means a lot.

Danzey is among those who believe that in regard to perceptions of DuPont in the Parkersburg community, theres a generational divide: Those in their 40s and younger tend to hold a less charitable view than baby boomers and their parents.

There likewise appears to be a generational divide in willingness to drink the water, despite the filtration installed as a result of the settlement.

On the September Saturday afternoon of the annual Parkersburg Paddlefest, kayaker Travis Hewitt, 31, stood ashore of the point where the Ohio meets the Little Kanawha and said that few people he knows truly believe the waters safe. Sure, he paddles in it, but I try not to get it on me and never swims in it. He has a filter installed in his kitchen.

Tommy Joyce, the mayor of Parkersburg, is bullish on West Virginia: Weve got enough coal to light the world, gas to heat the world and brains to run the world.

Fellow Parkersburg High grad Brian Flinn, an engineer, worked for DuPont for eight and a half years; he worked with the raw materials of Teflon. Hes seen both sides. Hes heard, If DuPont leaves, were done. This area will be like most other towns in West Virginia; itll collapse. Hes also aware of the inherent dangers in living within the shadow of the chemical industry. So the sentiment goes, he said, You take the good with the bad, right?

But Danzey is unwilling. I love West Virginia, she said. I really do. I love this state. I dont want to be anywhere else. But she wants better for West Virginians. Industries come into their communities, do well for a while, screw up the environment and then leave.

Its time for something new in West Virginia, she said. Its time for us to expect more.

Tracking the Health Impacts of C8 Exposure

Pondering that future keeps Ben Hawkins up at night. Whats next? Whats next for the community, and where does this end? Or does it? What sort of positivity can come to that community? They need it and they deserve it.

Hawkins asks this: Think about how loyal the people of the Parkersburg community have been to DuPont. What if they had the opportunity to extend that same loyalty to a company thats equally invested in the economic, physical and emotional health of the community?

Thats home and always will be home, Hawkins said of Parkersburg. We came from that community and that community did a lot to shape us. We all want the best for that community whatever form that can take.

##

Top photo: Tracy Danzey grew up in Parkersburg, West Virginia, but now lives on the opposite side of the state in its Eastern Panhandle. Danzey was diagnosed with a rare form of bone cancer that led to the amputation of her leg. Doctors couldnt trace the cause of the cancer, but Danzey believes it was caused by exposure to industrial waste in the waters of Parkersburg that she drank and swam in. Photo courtesy of Seth Freeman Photography

Good River: Stories of the Ohio is a series about the environment, economy and culture of the Ohio River watershed, produced by seven nonprofit newsrooms. To see more, please visit ohiowatershed.org.

Link:
A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences - alleghenyfront.org

Read More...

JSU MLK Convocation, UM MLK Day of Service and MSU Veterinary Camp – Jackson Free Press

January 10th, 2020 8:45 am

Constance Slaughter-Harvey, former Mississippi assistant secretary of state and general counsel, will deliver the keynote address at Jackson State University's annual Martin Luther King Jr. convocation on Friday, Jan. 17. Photo courtesy JSU

Jackson State University will host its annual Martin Luther King Jr. convocation on Friday, Jan. 17, inside the Rose E. McCoy Auditorium beginning at 10 a.m. Constance Slaughter-Harvey, former Mississippi assistant secretary of state and general counsel, will deliver the convocation's keynote address.

JSU's Margaret Walker Center will host its annual "For My People Awards" reception after the convocation in Student Center Ballroom A beginning at 11:30 a.m. Slaughter-Harvey will be one of the award recipients at this year's event, a release from JSU says.

Slaughter-Harvey became the first African American woman to receive a law degree from the University of Mississippi in 1970 and the first African American to serve as a judge in Mississippi in 1975. She is the founder and president of Legacy Education and Community Empowerment Foundation, Inc., and is a recipient of the American Bar Association's Margaret Brent Award and the Mississippi Bar's Susie Buchanan Award.

JSU's MLK convocation is part of a series of curated events at the university that pay tribute to the lives of Phillip Gibbs, a political science major at Jackson State College, and James Green, a student at Jim Hill High School.

City and state police, including the Mississippi Highway Patrol and 75 Jackson Police Department units, surrounded a group of students outside Alexander Hall, a women's dormitory at JSU, after reports that some of them were pelting rocks at traffic and starting fires on May 14, 1970. Shortly after midnight, police opened fire at the students, injuring 12 and killing Green and Gibbs.

Other events honoring Green and Gibbs include a student-led March of Remembrance and the 50th anniversary commemoration of the event in May 2020.

MLK Day of Service Events at UM

The University of Mississippi is hosting an inaugural community dinner commemorating the life and legacy of Martin Luther King Jr. on Friday, Jan. 17, beginning at 7 p.m. in the UM Student Union Ballroom. Leslie Burl McLemore, professor emeritus of political science at Jackson State University, will deliver the keynote address.

The theme of the event is "Martin Luther King Jr. and the Right to Vote: The Long Road to Freedom." The event is free and open to the public, but attendees must register online here.

UM will host its third annual community reading of "Letter from a Birmingham Jail" on Saturday, Jan. 18, at 5 p.m. at Off-Square Books in Oxford.

On Monday, Jan. 20, UM will hold the community opening ceremony for its MLK Day of Service from 8 a.m. to noon at Second Baptist Church (611 Jackson Ave. East, Oxford). Activities will include a community breakfast that St. Peter's Episcopal Church will sponsor, a canned food drive, a voter registration drive that the Urban League of Women Voters will sponsor, an NAACP membership drive and a community program honoring civil rights activists. UM will hold a march from Second Baptist to the Lafayette County Courthouse after the breakfast.

Also on Jan. 20, UM will hold a film screening at the Powerhouse Community Arts Center from 2 p.m. to 4 p.m., which the Oxford Film Festival and Southern Foodways Alliance will co-sponsor. Films will include "Yazoo Revisited" by David Rae Morris and two films from the SFA.

For more information about MLK Day of Service events, email Erin Payseur Oeth at [emailprotected] , Melanie Addington at [emailprotected], Lyn Roberts at [emailprotected] or Jerone Smith at [emailprotected].

MSU Taking Applications for Student Veterinary Camp

Mississippi State University's College of Veterinary Medicine will begin accepting applications for its 10th annual veterinary camp on Tuesday, Jan. 28. The camp is based on freshman and sophomore MSU veterinary courses and allows students ages 10 to 17 to study veterinary medicine under MSU faculty and doctorate students.

Students in the camp will participate in interactive labs and hands-on activities relating to small and large animal care, public health, animal pathology, research and pet health.

Applications are available online here. The submission deadline is noon on Friday, Feb. 28. For more information, call 662-325-4401 or visit cvm.msstate.edu.

Read the original:
JSU MLK Convocation, UM MLK Day of Service and MSU Veterinary Camp - Jackson Free Press

Read More...

So, you want to be a veterinary ophthalmologist? – Jill Lopez

January 10th, 2020 8:45 am

So, you want to be a veterinary ophthalmologist? Of course you do, its the best job on the planet earth! Who wouldnt want to be a veterinary ophthalmologist? After all, you get to help a variety of animals, their associated owners, practice at the highest level of veterinary medicine, help animals maintain vision, improve their comfort, and you get to perform eye saving procedures and help blind animals see again! So what does it take to get there?

Once enrolled in veterinary college, you must maintain a good grade average, obtain a four-year veterinary degree, and pass a national examination to be licensed to practice veterinary medicine in the United States. Most students at this point have also spent time helping with research, writing scientific papers, and shadowing an ophthalmologist to gain experience.

After the student has graduated from veterinary college, they then obtain a one-year rotating internship working with various specialists in disciplines such as ophthalmology, neurology, emergency/critical care, internal medicine, oncology, cardiology, radiology, surgery, dermatology, and others. At this time, they are eligible to apply to residencies in ophthalmology or a one-year specialty internship in ophthalmology. If one is not selected for a residency at this point, there are a few ophthalmology specialty internships where the candidate can continue to hone their ophthalmology skills and bolster their curriculum vitae for a residency position.

During an ophthalmology residency, which are typically three or four years, the resident works intently on only ophthalmic cases with specialized equipment under the direct supervision of an ABVO board certified veterinary ophthalmologist. The resident is learning current therapeutic measures to treat ophthalmic diseases and learning how to perform complicated surgical procedures.

At the completion of the residency, the residents mentor must acknowledge completion and the resident must pass a national board examination consisting of a three day test consisting of a written portion, an image recognition portion, and perform successful surgeries in front of ophthalmologists that are members of the ABVO Exam Committee. Whew! Talk about a long road!

As you can see, your veterinary ophthalmologist has been down a long road to make sure that your pet is receiving the best care for ophthalmic disease. If you are interested in a career in veterinary ophthalmology, a student should get started early and know that the road is not only longbut well worth it!

Excerpt from:
So, you want to be a veterinary ophthalmologist? - Jill Lopez

Read More...

Grantsville veterinarian’s remembrances of tales, tails and clientele – WV News

January 10th, 2020 8:45 am

GRANTSVILLE In the 43-year span of his veterinarian career, Dr. David Rawe of Grantsville has collected a vast accumulation of memories.

Detailed stories of many farm calls and office appointments fill his mind from over the years. Enough stories to fill a book. In fact, its something he has often thought of writing some day.

Even though it is from his love and compassion for animals that these memories were primarily gained, it seems its the friendships made with clients and appreciation for staff, which are foremost on his mind.

Rawe officially retired in June from a career that began in 1976 after graduation from Auburn Universitys College of Veterinary Medicine. He started practicing in Shelbyville, Kentucky, for a brief time, then spent two years in Lewisburg, West Virginia. He moved to Berlin in 1978, practicing at White Oak Vet Clinic with David Welch.

In 1982, David Rawe and his wife Camilla took a step out in faith to start their own practice in Grantsville at Casselman Veterinary Services. This move placed them near many people who were already his clients. The area he serviced encompassed southern Somerset County in Pennsylvania, Garrett County, Allegany County and Preston County in West Virginia.

The two struck a deal when they moved to Grantsville in those early years of their practice. If after two years there werent enough clients to make a go of it, then he would go back to working for another veterinarian.

Clientele grew quickly and after only six months, he was so busy, they had to hire another veterinarian to help with the workload.

Looking back on his career after his retirement, Rawe said, I really miss the cows and other animals, of course. But I miss talking with all the families even more. Most of my farm families, I watched their kids grow up, sharing the families happy times, as well as their sad.

Sometimes it feels a little bit like a bartender, he laughed. While working with their animals, we would talk and they would share things with me that maybe they couldnt tell everybody else.

As for the farmers, they looked forward to talking to him, as well because he always had a story or a good joke to tell, while sharing with him a story or a joke of their own. He was pleasant to work with, had a sense of humor, and always showed up with a smile on his face.

I have to admit, I didnt really like going out on farm calls in the middle of the night, but thats part of the job. Once I got out there and started working with the animal, with no one else around, the farmer and I would always have an enjoyable talk, Rawe said.

He mentioned that doing surgery was always his favorite part of the job, either on large or small animals. Again, showing his delight for conversation, he said, Once I got into the surgery far enough to make sure the animal was doing OK, especially on surgeries that were very common, the client and I could talk and get caught up on things.

Speaking of how the job took him away from his family at times, Rawe said, Sometimes I would take my kids along with me on farm calls. You never know what youre going to get into. I had two of them out with me until 1 a.m. one time. They fell asleep in the truck.

I remember taking my two youngest, Aaron and Emily, with me on a call for a horse with a long cut on its neck. Knowing that a horse can thrash around a lot when working with it, I told them they had to stay back so they wouldnt get hurt. It took some time to get the horse to settle down, and when we were done, I realized the kids were nowhere around. They had gotten scared, ran out to the truck, climbed up the tailgate and were sitting on the roof of the truck, he said, when referring to another late call-out.

Something Rawe enjoys as much as talking with his clients is fishing. Its something he has taken advantage of since his retirement. His staff can tell you that he had a fishing pole in his truck at all times and took the opportunity to go fishing whenever he had the chance, even during his veterinarian years.

Gladys Maust, a long-time employee of CVS, started working for David and Camilla Rawe in the early years.

He quickly learned which farms had good fishing ponds, Maust said. His large animal equipment included a fishing pole to sneak in a few relaxing moments ... I remember having to move his fishing pole every time I needed to get something out of his truck.

Maust often went along to assist on farm calls with Rawe and was familiar with most of the farms, including the ones with fishing ponds. When Rawe was leaving one of those farms on a particular day, he did not return to the office in the expected time, even though he was done for the day. His pager went off. Thinking he had an emergency call coming in, he was amused to see the message asking, How are the fish biting?

We always had great employees, Rawe said. They always did an excellent job, and we appreciated all the work they did for us.

The employees seem to feel the same about him.

He was an excellent veterinarian and boss, becoming a good friend over the years, Maust said. He worked many hours, often being on call 24/7, especially in the earlier years. Veterinary medicine can be a hard profession, but Dr. Rawes sense of humor helped us all through some tough moments. He truly cared, not only for all of his patients, but also their people.

Maust said one of the Amish clients told her that the Amish community appreciated Rawe greatly.

They felt he accepted everyone for who they were and involved himself in their lives on their level, she said.

Another employee since the early years is Karen Lytle.

One of the best things I did in my life was going to work for Dr. Rawe, Lytle said. He not only became my boss, but a great friend even though he enjoyed scaring me every chance he got.

From the very beginning, Dr. Rawe and his employees always put the patients and clients care first, which is why it has continued to grow into the practice it is today, she said.

Rawe said one person who definitely was not appreciated enough for all the work she did over the years was his wife, Camilla.

She is my rock in life, for all that has went on in the practice and now in our retirement. he said. She has done so much more than any wife or partner could ever do to support me. When we first opened the practice in Grantsville, we worked out of our house for the first few years. She would run all the samples, order supplies, take the calls from the customers and make appointments, deal with the salesmen, do the bookkeeping, and so on, and still took care of the house and six children.

Camillas work and presence was known and appreciated by her husband and staff, even after the business began operating out of the current building, which was built specifically for the practice.

In reflection, Rawe said, I was fortunate that I woke up every day and got to go to a job I really enjoyed. Maybe coming home tired every night weighed on me physically as I got older, but I still enjoyed it.

The one thing that was always hard was having to tell a client there was nothing more that could be done to save their animal, or finding out later that the animal had died. Having to euthanize a pet was always a sad decision never one made unless it was necessary. I always felt sad, along with the people, in times like those, wanting to be there for them when they needed some comfort, he said.

The clients always treated me so nice. I cant say the amount of meals that were given to me, stuff left on the truck seat for me, like cookies and other nice things. Everyone was very generous, and many friendships were formed.

In his retirement, there is plenty to do to keep the Rawes busy. While he misses his clients and staff greatly, he is glad his job was not the only interest he and Camilla had in their lives. They spend as much time together as possible now. They take time to visit and enjoy their children and grandchildren. Certain days of the week are earmarked for things such as visiting family, friends, neighbors, past clients and, of course, fishing.

Their love for music and volunteering at St Anns Catholic Church occupies much of their time as well. David Rawe has been involved with vocals and guitar since high school, and both help him in song leadership every Sunday.

Camilla Rawe has served in religious education for more than 50 years. She currently facilitates an adult Bible study class and serves on the Archdiocesan Pastoral Council, as well as the facilities and real estate commission. Both serve on the Mission Team for their local parish and visit the nursing home on Tuesdays.

Continued here:
Grantsville veterinarian's remembrances of tales, tails and clientele - WV News

Read More...

Global Nuclear Imaging Equipment Market 2019-2023 | Evolving Opportunities With Canon Inc. and Mediso Ltd. | Technavio – Business Wire

January 10th, 2020 8:45 am

LONDON--(BUSINESS WIRE)--The global nuclear imaging equipment market is poised to grow by USD 858.76 million during 2019-2023, progressing at a CAGR of over 6% during the forecast period. Request Free Sample Pages

Read the 137-page research report with TOC on "Nuclear Imaging Equipment Market Analysis Report by Product (SPECT systems, Hybrid PET systems, and Planar scintigraphy), by Application (Cardiology, Oncology, Neurology, and Others), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023".

https://www.technavio.com/report/global-nuclear-imaging-equipment-market-industry-analysis

The advancements in radiotracers and improvements in diagnostic imaging are anticipated to boost the growth of the market.

Advances in technology and clinical trends are leading to the development of new radiotracers. Radiotracer imaging such as F-18-fludeoxyglucose (F-18-FDG) is gaining popularity in veterinary medicine, especially in veterinary oncology, as it allows improved individualized tumor diagnosis and treatment. The introduction of molecular radiotracer imaging, including positron emission tomography (PET) and single photon emission computed tomography (SPECT) make PET/CT or PET/MRI promising imaging techniques. Such advances in radiotracers and their applications in scans are expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Nuclear Imaging Equipment Market Companies:

Canon Inc.

Canon Inc. is headquartered in Japan and operates the business under various segments such as Office, Imaging System, Industry and Others, and Medical System. The company offers PUREViSION Edition PET/CT system, Celesteion.

GE Healthcare Inc.

GE Healthcare Inc. is headquartered in the US and offers products through the following business units: Healthcare Systems and Life Sciences. The company offers NM 830, NM/CT 850, NM/CT 860, NM/CT 870 DR, NM/CT 870 CZT, Xeleris 4 DR, Discovery NM530c, Discovery MI, Discovery MI DR, and Discovery IQ.

Koninklijke Philips NV

Koninklijke Philips NV is headquartered in the Netherlands and operates under various business segments, namely Personal Health, Diagnosis & Treatment, Connected Care & Health Informatics, and Other. The company offers Vereos, Ingenuity TF, TruFlight Select, BrightView, BrightView XCT, and BrightView X.

Mediso Ltd.

Mediso Ltd. is headquartered in Hungary and offers products including AnyScan MultiScan LFER 150 PET/CT, and NanoSPECT/CT Silver Upgrade. The company also offers products such as nanoScan SPECT/MRI and nanoScan PET/MRI.

Neusoft Corp.

Neusoft Corp. is headquartered in China and offers NeuSight PET/CT. It comes with intelligent QC as well as high sensitivity and resolution and internally self-shielded quality control named Source.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Nuclear Imaging Equipment Product Outlook (Revenue, USD Million, 2019 - 2023)

Nuclear Imaging Equipment Regional Outlook (Revenue, USD Million, 2019 - 2023)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Automatic Cell Imaging System Market Global Automatic Cell Imaging System Market by end-users (hospitals, diagnostic laboratories, and others) and geography (Asia, Europe, North America, and ROW).

Medical Imaging Market Global Medical Imaging Market by product (X-ray imaging, ultrasound imaging, MRI, CT scanner imaging, and SPECT/PET imaging), application (radiology, cardiology, orthopedics, and others), and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read more:
Global Nuclear Imaging Equipment Market 2019-2023 | Evolving Opportunities With Canon Inc. and Mediso Ltd. | Technavio - Business Wire

Read More...

Saving Vulnerable Black Rhinos | Our Impact | Save The – Save the Rhino International

January 10th, 2020 8:45 am

Whether its a routine scan or a more complex operation, we all know that medical procedures come with risks. Of course, this is no different for veterinary procedures on any animal, and when it comes to rhinos, the fragility of a species adds an extra burden of worry. With fewer than 6,000 black rhinos left in the world, when one suddenly falls ill or is found with significant injuries, it is important to react quickly and provide expert care to the vulnerable black rhino.

In the wild, black rhino bulls are extremely territorial. They will fight other males found in their territory, often causing significant injuries to each other. Last year, Muya, a black rhino bull at Ol Jogi Conservancy, had to be treated by vets after he sustained substantial injuries during a fight. When vets examined Muya, they concluded that the injuries were most likely caused by the other rhinos horn. Thanks to the veterinary response, Muya made a full recovery and now continues to roam around Ol Jogi, hopefully staying within his own territory!

Another bull, Athi, was also treated at Ol Jogi, after a piece of wire became caught around his leg. Vets were able to remove the wire successfully and just like Muya, Athi also made a full recovery.

You may also remember a black rhino named Alfie from a recent blog; in 2012 rangers at Ol Jogi Conservancy realised that Alfie was blind. Alfies condition was likely something that he was born with and that he will live with for the rest of his life. Alfie is now cared for each day by rangers, particularly Peter, his main keeper. Alfie and Peter spend a lot of time together and Peter watches over Alfie while he roams outside of his enclosure each day.

All veterinary operations require extensive care and deployment of staff, aircraft and equipment. Thanks to funding from our supporters and donors, we were able to contribute towards these costs through the Black Rhino Emergency Fund, paying for veterinary medicine, darts, veterinary staff, aircraft and assistance of capture staff. The fund is made available for all black rhino emergency interventions for APLRS (Association of Private Land Rhino Sanctuaries) conservancies within Kenyas Laikipia County, providing 50% of all costs incurred, making it possible for animals like Muya, Athi and Alfie to receive the treatment they need quickly, whilst also reinforcing joint initiatives between conservancies, such as rhino monitoring, protection and general best practice.

In 2018-19, we were able to support successful emergency interventions for four black rhinos, each needing veterinary or hand-rearing care: Alfie, Muya, Athi and another rhino, Lojipu. Lojipu was abandoned by his mother just after he was born in February 2017. With no adult protection, Lojipu, was attacked by an older dominant male and had to be moved to a sanctuary for hand-rearing and treatment. In June 2018, Lojipu was relocated back to Sera Conservancy, where he will be cared for closely by rangers before being fully released into the wider Conservancy!

Unfortunately, not all interventions are successful and sadly, in the past year, two black rhino calves died due to the severity of their injuries and illnesses.

Every time a black rhino is found in distress, the emergency fund provides conservancies with the ability to react without causing a significant economic burden. In turn, teams can give the very best care to support the rhino in the long-term. Each time a vulnerable black rhinos health is restored, it brings more hope for the future of this iconic species.

View post:
Saving Vulnerable Black Rhinos | Our Impact | Save The - Save the Rhino International

Read More...

Pet Peeves: What will the New Year bring for you and your pet? – WZZM13.com

January 10th, 2020 8:45 am

GRAND RAPIDS, Mich. No matter how you celebrated New Years 2020, there is one tradition that should always be upheld, and that is making a New Years resolution. While you may be busy thinking about how you will get fit or which bad habits to ditch, it is important to keep some New Years resolutions in mind for your pet.

Veterinarians from BluePearl Specialty and Emergency Pet Hospital are encouraging pet owners to make New Years plans for pets, because just like us, they can benefit from changes to their wellness routines.

Pets cannot make resolutions on their own; only you, the owner, can do that. As we come into the new years and the new decade, it is important to remember that pets may also need to ditch those bad dietary habits and engage in a healthier lifestyle, said Yoojin Kim, DVM, veterinary internist at the BluePearl in Grand Rapids. This new year, try to set some achievable goals for your pet and stick to them. Ultimately, these resolutions will make for a happier and healthier pet.

Here are a few New Years resolution ideas that will help promote a happier and healthier year for your furry friend.

Take these five tips.

RELATED VIDEO:

More Pet Peeves on 13 ON YOUR SIDE:

Make it easy to keep up to date with more stories like this.Download the 13 ON YOUR SIDE app now.

Have a news tip? Email news@13onyourside.com, visit our Facebook page or Twitter. Subscribe to our YouTube channel.

Read the rest here:
Pet Peeves: What will the New Year bring for you and your pet? - WZZM13.com

Read More...

Page 765«..1020..764765766767..770780..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick